Labcorp (NYSE:LH) Releases FY 2026 Earnings Guidance

Labcorp (NYSE:LH) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 17.700-18.350 for the period, compared to the consensus estimate of 17.760. The company issued revenue guidance of $14.7 billion-$14.8 billion, compared to the consensus revenue estimate of $14.7 billion.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Robert W. Baird lifted their price target on Labcorp from $313.00 to $326.00 and gave the company an “outperform” rating in a research note on Wednesday, February 18th. Wall Street Zen lowered Labcorp from a “buy” rating to a “hold” rating in a research note on Saturday, April 4th. Piper Sandler lifted their price target on Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research note on Tuesday, February 24th. JPMorgan Chase & Co. lifted their price target on Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Finally, Evercore reissued an “outperform” rating and set a $300.00 price target on shares of Labcorp in a research note on Wednesday, April 8th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $307.20.

Labcorp Trading Down 0.1%

Shares of Labcorp stock traded down $0.25 during midday trading on Thursday, reaching $256.90. The company had a trading volume of 1,528,481 shares, compared to its average volume of 579,472. The stock has a fifty day moving average price of $270.69 and a 200 day moving average price of $267.48. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.42 and a quick ratio of 1.23. The firm has a market cap of $21.11 billion, a PE ratio of 24.56, a P/E/G ratio of 1.76 and a beta of 1.02. Labcorp has a fifty-two week low of $235.80 and a fifty-two week high of $293.72.

Labcorp (NYSE:LH) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $4.10 by $0.15. The company had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, equities analysts anticipate that Labcorp will post 17.67 earnings per share for the current year.

Labcorp Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Friday, May 29th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date of this dividend is Friday, May 29th. Labcorp’s payout ratio is currently 27.53%.

Insider Buying and Selling

In related news, EVP Brian J. Caveney sold 1,500 shares of Labcorp stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $286.31, for a total value of $429,465.00. Following the transaction, the executive vice president directly owned 30,107 shares of the company’s stock, valued at $8,619,935.17. The trade was a 4.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Der Vaart Sandra D. Van sold 548 shares of Labcorp stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $284.91, for a total value of $156,130.68. Following the completion of the sale, the executive vice president owned 2,579 shares of the company’s stock, valued at approximately $734,782.89. The trade was a 17.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 16,113 shares of company stock valued at $4,547,450 in the last ninety days. Insiders own 0.84% of the company’s stock.

Labcorp News Roundup

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Q1 results beat consensus — Labcorp posted EPS of $4.25 and revenue of $3.54B, both above estimates, with year-over-year revenue growth and margin improvement; positives for near-term earnings momentum. Labcorp Holdings (LH) Q1 Earnings and Revenues Top Estimates
• Positive Sentiment: Raised FY?2026 outlook — management increased its full?year profit and revenue guidance, citing steady diagnostics demand, which supports the company’s growth narrative. Labcorp raises full-year forecasts on steady diagnostics demand
• Positive Sentiment: Broad segment strength & analyst reaction — coverage notes growth across clinical labs and drug development services; pre?market reaction was positive after the beat and stronger guidance tone. LH Stock Up in Pre-Market on Q1 Earnings & Revenue Beat, 2026 View Up
• Neutral Sentiment: Guidance is in-line but nuanced — FY?26 EPS was set at $17.70–18.35 (consensus ~$17.76); the range overlaps street expectations but leaves room for interpretation on trajectory and margin assumptions. Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance
• Neutral Sentiment: More detail available — the full earnings call transcript and slide deck were released for investors who want line?item and segment detail before forming a longer-term view. Labcorp Holdings Inc. (LH) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Muted/negative near?term market reaction — despite the beat and higher guidance, LH shares slipped (with above?average volume), suggesting profit?taking or short?term skepticism about execution vs. the raised targets. Labcorp Q1 Press Release / Slide Deck

Institutional Investors Weigh In On Labcorp

A number of hedge funds have recently added to or reduced their stakes in LH. JPL Wealth Management LLC acquired a new position in shares of Labcorp during the third quarter worth approximately $28,000. DV Equities LLC bought a new stake in Labcorp during the 4th quarter valued at $29,000. EFG International AG bought a new stake in Labcorp during the 4th quarter valued at $33,000. Headlands Technologies LLC increased its stake in Labcorp by 300.0% during the 2nd quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 96 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its stake in Labcorp by 575.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 162 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 138 shares in the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.